Retrospective Cohort Analysis Examining the Efficacy and Safety of (V)DTPACE in Newly Diagnosed and Relapsed/Refractory Myeloma Patients – the UK Experience
Multiple myeloma remains incurable in spite of advances in treatment. In UK, combination of dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (DTPACE) continues to play a role in patients with relapsed/refractory multiple myeloma (RRMM), as bridge to transplant or for rapid tumor bulking. Recently, bortezomib has been included (VDTPACE), following favorable results from the TT3 study. However results outside the Arkansas group have been rarely reported.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Priya Sriskandarajah, Helen Jolly, Charlotte Pawlyn, Kabir Mohammed, Claire Dearden, Mike Potter, Faith Davies, Gareth Morgan, Kevin Boyd, Martin Kaiser Source Type: research
More News: Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Study | Transplants | Velcade